EW
SRPT icon

Evoke Wealth’s Sarepta Therapeutics SRPT Stock Holding History

Evoke Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19
Closed -$1K – 1229
2021
Q1 		$1K Hold
19
– – ﹤0.01% 1136
2020
Q4 		$3K Hold
19
– – ﹤0.01% 842
2020
Q3 		$3K Hold
19
– – ﹤0.01% 800
2020
Q2 		$3K Sell
19
-19
-50% -$2.59K ﹤0.01% 817
2020
Q1 		$3.72K Buy
+38
New +$4.34K ﹤0.01% 675
2019
Q4 		– Sell
-19
Closed -$1.43K – 1446
2019
Q3 		$1.43K Buy
+19
New +$2.24K ﹤0.01% 1270

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Evoke Wealth's SRPT Position: Q2 2021 in Review

Evoke Wealth sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 19 shares — an estimated $1K sold.

Evoke Wealth first reported a position in SRPT in Q3 2019 and held it in 6 quarters. The position peaked at $3.72K in Q1 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Evoke Wealth reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Evoke Wealth sold 19 Sarepta Therapeutics shares in Q2 2021, an estimated $1K.
  • Evoke Wealth first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 6 quarters.
  • Evoke Wealth's Sarepta Therapeutics position peaked at $3.72K in Q1 2020.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Evoke Wealth's 13F filing for Q2 2021, filed 5 Aug 2021.